AAP
ELDN icon

Arax Advisory Partners’s Eledon Pharmaceuticals ELDN Stock Holding History

Arax Advisory Partners’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.6K Buy
5,984
+5,961
+25,917% +$21.7K ﹤0.01% 3841
2026
Q1 		$157 Buy
+23
New +$54 ﹤0.01% 3572
2025
Q4 		– Sell
-152
Closed -$393 – 4209
2025
Q3 		$393 Buy
+152
New +$444 ﹤0.01% 3392

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Arax Advisory Partners's ELDN Position: Q2 2026 in Review

Arax Advisory Partners increased its Eledon Pharmaceuticals (ELDN) stake by 25,917% in Q2 2026, buying an estimated $21.7K and bringing the position to 5,984 shares worth $23.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3841.

Arax Advisory Partners first reported a position in ELDN in Q3 2025 and has held it in 3 quarters since. 161 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • Arax Advisory Partners held 5,984 shares of Eledon Pharmaceuticals worth $23.6K as of Q2 2026.
  • Arax Advisory Partners bought 5,961 Eledon Pharmaceuticals shares in Q2 2026, an estimated $21.7K.
  • Eledon Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3841 holding.
  • Arax Advisory Partners first reported a position in Eledon Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 161 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.